Appili Therapeutics to Present Live via Webcast at OTC Markets Virtual Life Sciences Investor Forum
09 Março 2022 - 10:19AM
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company”
or “Appili”), a biopharmaceutical company focused on drug
development for infectious diseases, today announced that Stéphane
Paquette, Vice President, Corporate Development, will present live
at the upcoming OTC Markets Life Sciences Investor Forum
at virtualinvestorconferences.com on March 10, 2022.
DATE: March 10, 2022TIME:
2:30-3:00 pm ETLINK: https://bit.ly/3vOOlum
This will be a live, interactive online event where investors
are invited to ask the company questions in real-time. If attendees
are not able to join the event live on the day of the conference,
an archived webcast will also be made available after the
event.
It is recommended that investors pre-register and run the online
system check to expedite participation and receive event
updates.
Learn more about the event at
www.virtualinvestorconferences.com.
Recent Company HighlightsThe Company will
provide an update on its pipeline of novel anti-infectives and
recent operational highlights, including:
- Over US$10M in new funding from the US
Department of Defense to advance biodefense vaccine candidate
ATI-1701, a leading and potential first-in-class option to prevent
infection by top priority biothreat Francisella tularensis
- Expansion of its commercial agreement
with Saptalis Pharmaceuticals to add European and Latin American
markets and increase global access to ATI-1501, Appili’s
proprietary taste-masked liquid suspension reformulation of
metronidazole scheduled for submission to the US Food and Drug
Administration later this year
About Appili TherapeuticsAppili
Therapeutics is an infectious disease biopharmaceutical company
that is purposefully built, portfolio-driven, and people-focused to
fulfill its mission of solving life-threatening infections. By
systematically identifying urgent infections with unmet needs,
Appili’s goal is to strategically develop a pipeline of novel
therapies to prevent deaths and improve lives. The Company is
currently advancing a diverse range of anti-infectives, including a
broad-spectrum antifungal, a vaccine candidate to eliminate a
serious biological weapon threat, and two novel antibiotic
programs. Led by a proven management team, Appili is at the
epicenter of the global fight against infection. For more
information, visit www.AppiliTherapeutics.com.
About Virtual Investor Conferences®Virtual
Investor Conferences (VIC) is the leading proprietary investor
conference series that provides an interactive forum for publicly
traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is
specifically designed to offer companies more efficient investor
access. Replicating the components of an on-site investor
conference, VIC offers companies enhanced capabilities to connect
with investors, schedule targeted one-on-one meetings and enhance
their presentations with dynamic video content. Accelerating the
next level of investor engagement, Virtual Investor Conferences
delivers leading investor communications to a global network of
retail and institutional investors.
Forward looking statementsThis news release
contains “forward-looking statements”, including with respect to
anticipated funding from the US Department of Defense. Wherever
possible, words such as “may,” “would,” “could,” “should,” “will,”
“anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,”
“potential for” and similar expressions have been used to identify
these forward-looking statements. These forward-looking statements
reflect the current expectations of the Company’s management for
future growth, results of operations, performance and business
prospects and opportunities and involve significant known and
unknown risks, uncertainties and assumptions, including, without
limitation, those listed in the annual information form of the
Company dated June 23, 2021 and the other filings made by the
Company with the Canadian securities regulatory authorities (which
may be viewed at www.sedar.com). Should one or more of these
risks or uncertainties materialize or should assumptions underlying
the forward-looking statements prove incorrect, actual results,
performance or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. These factors should be considered carefully,
and prospective investors should not place undue reliance on the
forward-looking statements. The Company disclaims any intention or
obligation to revise forward-looking statements whether as a result
of new information, future developments or otherwise, except as
required by law.
CONTACTS:Appili
TherapeuticsStéphane PaquetteVice President, Corporate
DevelopmentAppili TherapeuticsInfo@AppiliTherapeutics.com
Virtual Investor ConferencesJohn M. ViglottiSVP
Corporate Services, Investor AccessOTC Markets Group (212)
220-2221johnv@otcmarkets.com
Appili Therapeutics (TSX:APLI)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Appili Therapeutics (TSX:APLI)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024